Bolt Biotherapeutics enrolls first patient in Phase 2 study of BDC-1001

Bolt Biotherapeutic announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate, ISAC, as a single agent and in combination with the HER2-targeting antibody pertuzumab. The first patient was treated at City of Hope. “Patients with HER2-positive breast cancer who progress after Enhertu have few therapeutic options,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. “BDC-1001 has a unique mechanism of action compared to available agents, mobilizing the patient’s immune system to fight cancer. This provides scientific and clinical rationale for this new study. This is also our first opportunity to clinically validate the compelling anti-tumor activity we saw preclinically when combining BDC-1001 surrogate with pertuzumab.”